M Peeters

Summary

Affiliation: University Hospital Antwerp
Country: Belgium

Publications

  1. pmc Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members
    Sarah Pringels
    Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Zwijnaarde, 9052, Belgium
    BMC Cancer 12:515. 2012
  2. doi request reprint Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    Clin Cancer Res 19:1902-12. 2013
  3. pmc A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
    M Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    Br J Cancer 108:503-11. 2013
  4. doi request reprint Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    J Clin Oncol 31:759-65. 2013
  5. pmc LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
    Carl Christoph Schimanski
    First Deptartment of Internal Medicine, University Medical Center UMC, University Hospital of Mainz, Mainz, Germany
    BMC Cancer 12:144. 2012
  6. doi request reprint Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
    Cancer Treat Rev 38:397-406. 2012
  7. doi request reprint Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    Marc Peeters
    University Hospital Ghent, Ghent, Belgium
    J Clin Oncol 28:4706-13. 2010
  8. ncbi request reprint Diarrhea and the rationale to use Sandostatin
    M Peeters
    Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, Edegem
    Acta Gastroenterol Belg 73:25-36. 2010
  9. doi request reprint Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases
    Jeroen Mertens
    Department of Nuclear Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium
    Eur J Nucl Med Mol Imaging 40:1214-22. 2013
  10. ncbi request reprint Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer
    M Peeters
    Department of Hepatogastroenterology, Digestive Oncology Unit, University Hospital Ghent, Gent, Belgium
    Aliment Pharmacol Ther 28:269-81. 2008

Collaborators

Detail Information

Publications20

  1. pmc Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members
    Sarah Pringels
    Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Zwijnaarde, 9052, Belgium
    BMC Cancer 12:515. 2012
    ..These studies, which used specimens obtained by surgical resection or colonoscopic biopsy, yielded contradictory results. We studied the effect of the sampling method on the marker accuracy of VEGF family members...
  2. doi request reprint Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    Clin Cancer Res 19:1902-12. 2013
    ..To investigate whether EGF receptor (EGFR) pathway mutations predicted response to monotherapy with panitumumab, an anti-EGFR monoclonal antibody, in a randomized phase III study of metastatic colorectal cancer...
  3. pmc A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
    M Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    Br J Cancer 108:503-11. 2013
    ....
  4. doi request reprint Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Edegem, Belgium
    J Clin Oncol 31:759-65. 2013
    ..This retrospective analysis of three randomized phase III studies assessed the prognostic and predictive impact of individual mutant KRAS codon 12 and 13 alleles...
  5. pmc LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
    Carl Christoph Schimanski
    First Deptartment of Internal Medicine, University Medical Center UMC, University Hospital of Mainz, Mainz, Germany
    BMC Cancer 12:144. 2012
    ..In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC...
  6. doi request reprint Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice
    Marc Peeters
    Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
    Cancer Treat Rev 38:397-406. 2012
    ..Therefore, here, we review and distil the currently available data reported from phase III trials of biologic agents in the first-, second- and third-line mCRC settings...
  7. doi request reprint Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    Marc Peeters
    University Hospital Ghent, Ghent, Belgium
    J Clin Oncol 28:4706-13. 2010
    ..This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status...
  8. ncbi request reprint Diarrhea and the rationale to use Sandostatin
    M Peeters
    Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, Edegem
    Acta Gastroenterol Belg 73:25-36. 2010
    ....
  9. doi request reprint Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases
    Jeroen Mertens
    Department of Nuclear Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium
    Eur J Nucl Med Mol Imaging 40:1214-22. 2013
    ..The potential role of this parameter in the assessment of response to chemotherapy and bevacizumab was tested in patients with metastatic colorectal cancer with potentially resectable liver metastases (mCRC)...
  10. ncbi request reprint Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer
    M Peeters
    Department of Hepatogastroenterology, Digestive Oncology Unit, University Hospital Ghent, Gent, Belgium
    Aliment Pharmacol Ther 28:269-81. 2008
    ..Panitumumab is a fully human monoclonal IgG2 antibody targeting the epidermal growth factor receptor (EGFR)...
  11. ncbi request reprint The role of surgery and transplantation in neuroendocrine tumours
    G Roeyen
    Department of Hepatobiliary, Endocrine and Transplantation Surgery, University Hospital Antwerp, Edegem, Belgium
    Acta Gastroenterol Belg 72:39-43. 2009
    ..Especially in ileal NETs aggressive surgical therapy is recommended because of prevention of long-term complications, which may improve survival...
  12. pmc The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
    I Debergh
    Department of Surgery, University Hospital, De Pintelaan 185, Ghent, Belgium
    Br J Cancer 102:837-43. 2010
    ..We aimed to examine the effects of nadroparin on tumour angiogenesis using a dorsal skinfold window chamber model in the Syrian hamster...
  13. doi request reprint Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study
    S Laurent
    Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium
    Ann Oncol 20:1369-74. 2009
    ..The prognosis of pancreaticobiliary tumors is poor. The aim was to assess the feasibility of radiotherapy (RT) and concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma...
  14. ncbi request reprint Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium
    E Macken
    Department of Gastroenterology, UZ Antwerp, Belgium
    Acta Gastroenterol Belg 72:17-25. 2009
    ..Our goal of this update is to provide practical guidelines for endoscopists performing screening colonoscopy. We hope to provide a broad consensus and an increasing adherence to these recommendations...
  15. ncbi request reprint The role of oral fluoropyrimidines in the treatment of advanced gastric cancer
    A Pieters
    Department of Gastroenterology, Digestive Oncology Unit, University Hospital Ghent, Belgium
    Acta Gastroenterol Belg 71:361-6. 2008
    ..As a single agent, it has not undergone large scale randomised studies. S-1, another oral fluoropyrimidine, is a potential challenger to the role of capecitabine, but is lacking phase III data in Western population...
  16. doi request reprint In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC
    W Bouquet
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Ann Surg Oncol 17:2510-7. 2010
    ..In this study, a novel paclitaxel (Pac) formulation was investigated for its toxicity and bioavailability during HIPEC compared with Taxol...
  17. ncbi request reprint Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors
    C Van de Wiele
    Department of Nuclear Medicine, University Hospital Ghent, Ghent, Belgium
    Q J Nucl Med Mol Imaging 53:317-24. 2009
    ....
  18. ncbi request reprint Systemic chemotherapy in patients with peritoneal carcinomatosis from non colorectal origin
    S Van Lierde
    Department of Gastroenterology, University Hospital, Ghent, Belgium
    Cancer Treat Res 134:441-8. 2007
  19. pmc Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels
    W Ceelen
    Department of Surgery, Ghent University Hospital, Ghent, Belgium
    Br J Cancer 96:692-700. 2007
    ..Direct effects of rhEPO on neoplastic endothelium are likely to explain these findings in addition to indirect effects induced by increased oxygenation...
  20. ncbi request reprint Metastatic follicular dendritic cell sarcoma of the stomach: a case report and review of the literature
    A Geerts
    Department of Gastroenterology, University Hospital Ghent, Ghent, Belgium
    Acta Gastroenterol Belg 67:223-7. 2004
    ..Due to its rarity, a FDC sarcoma seldom enters the differential diagnosis of spindle cells neoplasms of the gastrointestinal tract. Complete surgical resection is the treatment of choice for FDC sarcoma...